Media Inquiries

Beth Calitri

Corporate Communications, Media Relations


[email protected]
Sort by Year
June 3, 2019

Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

May 9, 2019

Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

May 7, 2019

Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

May 2, 2019

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

April 18, 2019

Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

April 16, 2019

Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

April 1, 2019

Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

March 14, 2019

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

March 7, 2019

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

March 4, 2019

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

February 26, 2019

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

February 21, 2019

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

February 13, 2019

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

January 28, 2019

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

January 28, 2019

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

Copyright © 2022, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.